Table 8: Other Drugs That Have Been Used in the Setting of Recurrent Ovarian Cancer (Efficacy Not Well Defined After Failure of Platinum-Containing Regimens)
| Drugs | Drug Class | Major Toxicities | Comments |
| Etoposide | Topoisomerase II inhibitor | Myelosuppression; alopecia | Oral; rare leukemia dampens interest |
| Cyclophosphamide and several other bischloroethylamines | Alkylating agents | Myelosuppression; alopecia (only the oxazaphosphorines) | Leukemia and cystitis; uncertain activity after platinums |
| Hexamethylmelamine (Altretamine) | Unknown but probably alkylating prodrugs | Emesis and neurotoxicity | Oral; uncertain activity after platinums |
| Irinotecan | Topoisomerase I inhibitor | Diarrhea and other gastrointestinal symptoms | Cross-resistant to topotecan |
| Oxaliplatin | Platinum | Neuropathy, emesis, myelosuppression | Cross-resistant to usual platinums, but less so |
| Vinorelbine | Mitotic inhibitor | Myelosuppression | Erratic activity |
| Fluorouracil and capecitabine | Fluoropyrimidine antimetabolites | Gastrointestinal symptoms and myelosuppression | Capecitabine is oral; may be useful in mucinous tumors |
| Pemetrexed | Folic acid antagonist | Myelosuppression, rash | Under study in combinations with carboplatin |
| Tamoxifen | Antiestrogen | Thromboembolism | Oral; minimal activity, perhaps more in subsets |
